VIENNA, Austria, October 22 /PRNewswire/ -- New data presented at the United European Gastroenterology Week (UEGW) confirm the efficacy and safety of prucalopride, a novel enterokinetic compound, in patients with chronic constipation for whom laxatives do not provide adequate relief.

Prucalopride was evaluated in a large double-blind (n=231), placebo-controlled, phase II dose-finding trial (USA-3) that supports the choice of 2 mg as the lowest effective dose. Both the 2 mg and 4 mg dosing of prucalopride were superior to the 0.5 mg and 1 mg dosing with 4 mg showing a marginal benefit over 2 mg but a less favourable AE profile. There was no rebound effect during the run-out phase. Prucalopride was well tolerated at all doses tested.

LONDON, October 22 /PRNewswire/ -- Diabetic Hypoglycaemia (http://www.hypodiab.com), the influential online diabetes journal published by ESP Bioscience, leads its new issue with a topical editorial, authored by Professor Simon Heller, one of the ADVANCE investigators, and Dr Rory McCrimmon. The impact of intensive lowering of blood glucose levels on cardiac mortality was studied in the ACCORD and ADVANCE trials, and the outcomes of these trials suggested very different conclusions. Results from the ACCORD trial certainly suggest that aggressive lowering of blood glucose using multiple therapies to target an HbA1c of 6% or below is unsafe in some patients with type 2 diabetes; the trial was terminated due to an unexpected increase in the number of sudden cardiac deaths.

REDMOND, Washington and LANGLEY, England, October 22 /PRNewswire/ --

Microsoft Corp. and Travelport today announced they are teaming together to develop an integrated set of services targeted for the travel industry to address challenges faced by travellers, suppliers, and travel agents. Through the collaboration, Microsoft and Travelport will explore the development of services designed to improve the traveller experience and to provide airlines, travel suppliers, and travel agencies, including travel management companies (TMCs) and online travel agents (OTAs), with new revenue and cost reduction opportunities, broader distribution reach, and improved customer satisfaction and loyalty. The services are slated for Q1 2009.

LONDON, October 22 /PRNewswire/ -- A new and exciting site for online shopping has just opened its doors for business in the UK. Funkbet.com allows customers to find fantastic opportunities to buy the latest and greatest products 80-90% below the normal retail price.

The shoppers can achieve this by competing against other shoppers to find the lowest unique bid for the product on offer. This is exactly the opposite of the more famous auctions sites, like eBay.com where the products go to the highest bidder.

COPENHAGEN, October 22 /PRNewswire/ -- Breakthrough: Results from the fourth year in a long-term clinical study prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment.

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a persistent, positive effect on the immune system indicating a lasting tolerance to grass pollen.

INGELHEIM, Germany, October 22 /PRNewswire/ --

- BI 6727, a Highly Potent and Selective Plk1 inhibitor, Represents Latest Advance in Company's Plk1 Programme

- For non-US Healthcare Media